Antipsychotic drugs increase Neuregulin1β1 serum levels in first-episode drug-naive patients and chronic schizophrenia with suggestions for improving the treatment of psychotic symptoms.

ABSTRACT:

Background

Neuregulin1 (NRG1) plays a role in neuronal migration, regulation of synaptic plasticity, and neural survival, and has been considered to be among the candidate genes for schizophrenia. This study focused on the variations in serum NRG1β1 levels following antipsychotic treatment and the relationship between NRG1β1 levels and improvements in psychotic symptoms among first-episode drug-naïve (FEDN) patients and patients with chronic schizophrenia.

Methods

A total of 100 patients with schizophrenia were recruited and compared with 79 matched healthy controls. All patients had been drug-naïve for at least four weeks. Serum NRG1β1 levels and positive and negative syndrome scale (PANSS) scores were measured at baseline and after four weeks. Serum NRG1β1 levels were meas

SUBMITTER: Yang H 

PROVIDER: S-EPMC8957169 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature